Our meta-analysis underscores the significant therapeutic efficacy of low-dose, long-term rituximab regimens for PLA2R-associated primary MGN, particularly demonstrating sustained efficacy in extended follow-up. The gene discussed is PLA2R1; the disease is idiopathic membranous glomerulonephritis.